[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 2003, 29(5) 291-293 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
��ϸ������
B�ܰ�ϸ��
����Ǵ�,ϵͳ��
���������������
���
�����
PubMed
Article by
Article by

B�ܰ�ϸ���̼�����ϵͳ�Ժ���Ǵ����о���չ

���, �����

���пƼ���ѧͬ��ҽѧԺ����Э��ҽԺƤ���� �人 430022

ժҪ��

B�ܰ�ϸ���̼����������������Ӽ�����³�Ա,�����Bϸ���ĵ���,�ٽ�Bϸ���Ļ����ֳ,�ӳ�Bϸ���Ĵ��ʱ��ȡ�B�ܰ�ϸ���̼�����ϵͳ�Ժ���Ǵ��������ڵı�������ϵ���������B�ܰ�ϸ���̼���ķ��ӽṹ������ѧ�����Լ���ϵͳ�Ժ���Ǵ��ķ�����������Ƶȷ�����о���չ��

�ؼ����� ��ϸ������   B�ܰ�ϸ��   ����Ǵ�,ϵͳ��  

Abstract:

Keywords:
�ո����� 2002-11-12 �޻�����  ����淢������  
DOI:
������Ŀ:

ͨѶ����:
���߼��:

�ο����ף�
[1] Moore PA,Belvedere O,Orr A,et al.BLyS:member of the tumor necrosis factor family and B lymphocyte stimulator.Science,1999,285(5425):260-263.
[2] Schneider P,MacKay F,Steiner V,et al.BAFF,a novel ligand of the tumor necrosis factor family,stimulates B cell growth.J Exp Med,1999,189(11):1747-1756.
[3] Shu HB,Hu WH,Johnson H.TALL-1 is a novel member of the TNF family that is down-regulated by mitogens.J Leukoc Biol,1999,65(5):680-683.
[4] Mukhopadhyay A,Ni J,Zhai Y,et al.Identification and characterization of a novel cytokine,THANK,a TNF homologue that activates apoptosis,nuclear factor-kappaB,and c-Jun NH2-terminal kinase.J Biol Chem,1999,274(23):15978-15981.
[5] Nardelli B,Belvedere O,Roschke V,et al.Synthesis and release of B-lymphocyte stimulator from myeloid cells.Blood,2001,97(1):198-204.
[6] Gross JA,Johnston J,Mudri S,et al.TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.Nature,2000,404(6781):995-999.
[7] Thompson JS,Bixler SA,Qian F,et al.BAFF-R,a newly identified TNF receptor that specifically interacts with BAFF.Science,2001,293(5537):2108-2111.
[8] Wang H,Marsters SA,Baker T,et al.TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice.Nat Immunol,2001,2(7):632-637.
[9] Mackay F,Woodcock SA,Lawton P,et al.Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.J Exp Med,1999,190(11):1697-1710.
[10] Khare SD,Sarosi I,Xia XZ,et al.Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice.Proc Natl Acad Sci U S A,2000,97(7):3370-3375.
[11] Yu G,Boone T,Delaney J,et al.APRIL and TALL-I and receptors BCMA and TACI:system for regulating humoral immunity.Nat Immunol,2000,1(3):252-256.
[12] Stohl W.Systemic lupus erythematosus:a blissless disease of too much BLyS(B lymphocyte stimulator) protein.Curr Opin Rheumatol,2002,14(5):522-528.
[13] Yan M,Brady JR,Chan B,et al.Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency.Curr Biol,2001,11(19):1547-1552.
[14] Yan M,Wang H,Chan B,et al.Activation and accumulation of B cells in TACI-deficient mice.Nat Immunol,2001,2(7):638-643.
[15] Schiemann B,Gommerman JL,Vora K,et al.An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway.Science,2001,293(5537):2111-2114.
[16] Llorente L,Richaud-Patin Y,Wijdenes J,et al.Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus.Eur Cytokine Netw,1993,4(6):421-427.
[17] Viallard JF,Pellegrin JL,Ranchin V,et al.Th1(IL-2,interferon-gamma(IFN-gamma)) and Th2(IL-10,IL-4) cytokine production by peripheral blood mononuclear cells(PBMC) from patients with systemic lupus erythematosus(SLE).Clin Exp Immunol,1999,115(1):189-195.
[18] Hagiwara E,Gourley MF,Lee S,et al.Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood.Arthritis Rheum,1996,39(3):379-385.
[19] Miret C,Font J,Molina R,et al.Relationship of oncogenes(sFas,Bcl-2) and cytokines(IL-10,alfa-TNF) with the activity of systemic lupus erythematosus.Anticancer Res,2001,21(4B):3053-3059.
[20] Gescuk BD,Davis JC Jr.Novel therapeutic agents for systemic lupus erythematosus.Curr Opin Rheumatol,2002,14(5):515-521.
�������������
1��������,��ѧ˼,��ǧ��.�׽���12���������õĽ�չ[J]. ����Ƥ���Բ�ѧ��־, 2008,34(5): 330-332
2�������,����,������,��·��,�����,���̻�,��ҵ��,������,.Ѫ��IL-15��IL-21��IgEˮƽ��ݡ����Ĺ�ϵ[J]. ����Ƥ���Բ�ѧ��־, 2009,35(1): 3-5
3������ ������ ����Ȫ ���� ��ǧ��.÷�����߰׽���4��Toll������2���򵥺������̬���о�[J]. ����Ƥ���Բ�ѧ��־, 2010,36(6): 306-308
4��Ȩ�� ��ɭ ��ѧ��.�׽���-10����м��[J]. ����Ƥ���Բ�ѧ��־, 2006,32(6): 380-380
5���ﱾ�� ¬�췼 �����.�׽���-19��20��24����м���Ĺ�ϵ[J]. ����Ƥ���Բ�ѧ��־, 2007,33(2): 89-89
6������ ��٩ ���tȺ.IL-23/Th17ϸ��/IL-17ͨ·��Ƥ���Ƶ��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2012,38(6): 393-396
7��Ҧ��, ��־ǿ, ������.�׽���4���׽���10��������̬�Ե���״[J]. ����Ƥ���Բ�ѧ��־, 2004,30(4): 241-243
8�����, ���̸�.��ϵͳ��ӲƤ����ص�ϸ������[J]. ����Ƥ���Բ�ѧ��־, 2005,31(4): 235-237
9��Ȩ��, ��ɭ, ��ѧ��.�׽���-10����м��[J]. ����Ƥ���Բ�ѧ��־, 2006,32(6): 380-382
10���ﱾ��, ¬�췼, �����.�׽���-19,20��24����м���Ĺ�ϵ[J]. ����Ƥ���Բ�ѧ��־, 2007,33(2): 89-91
11���콨��, �¾�, �ƽ���.�׽���-23����м���Ĺ�ϵ[J]. ����Ƥ���Բ�ѧ��־, 2007,33(3): 177-179
12������ Ф����.��Ӧ��Ƥ����׽���-13[J]. ����Ƥ���Բ�ѧ��־, 2013,39(6): 365-367
13���βʷ� ���ػ�.��м���ķ�����׽���23/Th17��Th1-Th2-Th17��������-κB;�����о���չ[J]. ����Ƥ���Բ�ѧ��־, 2014,40(4): 228-230
14����Ң Ф����.IL-23/IL-17��������������Ƥ�������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2014,40(5): 313-315
15����ӱ�� ֣��.�����ܰ���ϸ��2����Ӧ��Ƥ�׵��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2016,42(4): 236-238
16�������� ʷ����.��ϸ������12��������м�����������е��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2017,43(2): 80-83
17��÷���� ������.��֦�˾���ؿ����ĵ��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2017,43(3): 177-180

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־